PET-CT在胃肠道间质瘤中的应用

冼伟均; 冯彦林

doi:10.3760/cma.j.issn.1673-4114.2009.03.004

PET-CT在胃肠道间质瘤中的应用

冼伟均 , 冯彦林

文章导航 > 国际放射医学核医学杂志 > 2009, 33 > 3: (140-143)

引用本文:

Citation:

PET-CT在胃肠道间质瘤中的应用

冼伟均,
冯彦林^,

佛山市第一人民医院核医学科, 佛山 528000

通讯作者: 冯彦林, jambool@126.com

The application of PET-CT in gastrointestinal stromal tumor

XIAN Wei-jun,
FENG Yan-lin^,

Department of Nu clear Medicine, The First People's Hospital ofFoshan, Foshan 528000, China

Corresponding author: FENG Yan-lin, jambool@126.com

摘要: 胃肠道间质瘤是一种主要生长在胃肠道的具有恶性潜能的间叶源性肿瘤,由于缺乏特异性的体征,影像学检查是诊断胃肠道间质瘤的重要辅助方法。PET-CT在胃肠道间质瘤的分期、疗效评价及随访方而与常规影像学检查相比,均表现出独特的优越性,该文综述了PET-CT及相关影像学技术在胃肠道间质瘤方面的应用价值。
- 胃肠道间质肿瘤 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机
Abstract: Gastrointestinal stromal tumor (GIST)is a mesenchymal neoplasm of uncertain malignant potential that arises predominantly in the gastrointestinal tract. Due to lack of specific physical signs, imagin g-x examination is an important auxiliary means in diagnosing gastrointestinal stromal tumor. Compared to other conventional imaging examinations, PET-CT has demonstrated unique superiority in staging, response evaluation and follow-up of gastrointestinal stromal tumor. And now it presents an overview of the application valuation of PET-CT and related imaging technology in gastrointestinal stromal tumor as follow.
- Gstrointestinal stromal tumors /
- Positron emission tomography /
- Tomography,X-ray computed
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	林苏,刘懿.胃肠道间质瘤.国外医学·消化系疾病分册,2005,25(1):25-28.
[2]	Miettinen M. Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach:a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol, 2005, 29(1):52-68.
[3]	邓伟雄,庄思敏,温东东,等.恶性胃肠道间质瘤25例诊治体会.广东医学,2004,25(4):432-433.
[4]	Mazur MI, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 1983, 7(6):507-519.
[5]	Miettinen M, Lasota J. Gastrointestinal stromal tumors-deftnition, clinical, histological, immunohistochemical, and molecular genetic features and diferential diagnosis. Virchows Arch, 2001, 438(1):1-12.
[6]	Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol, 2004, 22(18):3813-3825.
[7]	Mignon F, Julié C, Izzillo R, et al. Imaging features of gastric stromal tumors:radiologic-pathologic correlation. Report of 4 cases. J Radiol, 2000, 81(8):874-881.
[8]	王冬青,曾蒙苏,饶圣祥,等.CT在胃肠道间质瘤诊断及随访中的价值.实用放射学杂志,2006,22(6):695-697.
[9]	Ji F,Wang ZW, Wang LJ, et al. Clinicopathological characteristics of gastrointestinal mesenchymal tumors and diagnostic value of endoscopic uhrasonography. J Gastroenterol Hepatol, 2008, 23(8pt z):e318-e324.
[10]	宋建兵,汤继军,郭应兴,等.影像学检查对胃肠道间质瘤诊断价值的临床分析.实用放射学杂志,2006,22(7):832-834.
[11]	Kamiyama Y, Aihara R, Nakabayashi T, et al. ¹⁸F-fluorodeoxyglucose positron emission tomography:useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg, 2005, 29(11):1429-1435.
[12]	Steigen SE, Bjerkehagen B, Haugland HK, et al. Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Pathol, 2008, 21(1):46-53.
[13]	Wong NA, Young R, Malcomson RD, et al. Prognostic indicators for gastrointestinal stromal tumors:a clinicopathological and immunohistochemical study of 108 resected cases of the stomach.Histopathology, 2003, 43(2):118-126.
[14]	周立群,陈剑秋.胃肠道间质瘤的诊治研究进展.医学综述,2008,14(11):1467-1468.
[15]	万德森,伍小军,梁小曼,等.胃肠道间质瘤的外科治疗.中华胃肠外科杂志,2003,6(5):288-291.
[16]	Demetri GD, van Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7):472-480.
[17]	Nishida T, Shirao K, Sawaki A, et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advaneed gastrointestinal stromal tumors:a phase II study(ST1871B1202). Int J Clin Oncol, 2008, 13(3):244-251.
[18]	Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med, 2004, 45(3):357-365.
[19]	Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours:long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging, 2005, 32(2):153-162.
[20]	张孝平,管建国.甲磺酸伊马替尼在胃肠道间质瘤中的应用.基础医学论坛,2007,11(9):456-457.
[21]	Trent JC, Ramdas L, Dupart J, et al. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer, 2006, 107(8):1898-1908.
[22]	Stroobants S, Goeminne J, Seegers M, et al. ¹⁸FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer, 2003, 39(14):2012-2020.
[23]	Heinicke T, Wardelmann E, Sauerbnlch T, et al. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumors using ¹⁸fluoro-deoxyglucose-positron emission tomography. Anticancer Res, 2005, 25(6C):4591-4594.
[24]	万德森.胃肠道间质瘤术后复发转移的治疗.肿瘤研究与临床,2006,18(8):524-526.
[25]	DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival. Ann Surg, 2000, 231(1):51-58.
[26]	Sobhani I, Tiret E, Lebtahi R, et al. Early detection of recurrence by ¹⁸FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer, 2008, 98(5):875-880.

[1]	汪太松 , 赵晋华 , 宋建华 . PET-MRI和多模式肿瘤显像. 国际放射医学核医学杂志, 2011, 35(5): 261-264. doi: 10.3760/cma.j.issn.1673-4114.2011.05.002
[2]	沈国华 , 周惠君 , 邓候富 , 贾志云 . ⁶⁸Ga标记的SSR靶向多肽PET/CT显像的研究进展及其在神经内分泌肿瘤中的初步应用. 国际放射医学核医学杂志, 2015, 39(1): 75-79. doi: 10.3760/cma.j.issn.1673-4114.2015.01.016
[3]	王冬艳 , 苏成海 . PET、PEP-CT与磁共振弥散加权成像在肿瘤诊断中的对比研究进展. 国际放射医学核医学杂志, 2011, 35(6): 339-346. doi: 10.3760,cma.j.issn.1673-4114.2011.06.005
[4]	秦文琼 , 高硕 . PET/CT与临床预后因素在弥漫大B细胞淋巴瘤疗效评价及预后评估中的应用. 国际放射医学核医学杂志, 2017, 41(6): 437-442. doi: 10.3760/cma.j.issn.1673-4114.2017.06.010
[5]	叶慧 , 莫逸 , 谢爱民 , 彭翔 . ¹⁸F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究. 国际放射医学核医学杂志, 2008, 32(3): 147-150.
[6]	翟歌 , 李彪 . PET-CT全身显像甲状腺意外摄取¹⁸F-FDG的临床价值. 国际放射医学核医学杂志, 2009, 33(4): 235-237. doi: 10.3760/cma.j.issn.1673-4114.2009.04.013
[7]	肖杰 , 修雁 , 张洁 , 金莉蓉 , 石洪成 . 散发型克雅病脑¹⁸F-FDG PET/CT显像一例. 国际放射医学核医学杂志, 2017, 41(1): 74-75. doi: 10.3760/cma.j.issn.1673-4114.2017.01.014
[8]	孙茉茉 , 李剑明 . PET心肌灌注显像及其定量分析的研究进展. 国际放射医学核医学杂志, 2017, 41(6): 423-429. doi: 10.3760/cma.j.issn.1673-4114.2017.06.008
[9]	段钰 , 邓小虎 , 赵增鹏 , 周海中 . 左股骨朗格汉斯细胞组织细胞增生症PET/CT显像一例. 国际放射医学核医学杂志, 2017, 41(6): 452-454. doi: 10.3760/cma.j.issn.1673-4114.2017.06.013
[10]	寿毅 , 姜建隽 , 王海岩 , 蒋艳 , 宋结平 , 尤志雯 , 孟庆元 , 陈兴 , 赵军 . PET/CT显像恶性单发肺结节边缘征象与所对应区域¹⁸F-FDG代谢程度的关系研究. 国际放射医学核医学杂志, 2018, 42(2): 97-103. doi: 10.3760/cma.j.issn.1673-4114.2018.02.001
[11]	段钰 , 邓小虎 , 徐迟峰 , 周海中 . 面部原发性外周T细胞淋巴瘤-非特指型¹⁸F-FDG PET/CT显像一例. 国际放射医学核医学杂志, 2017, 41(6): 455-457. doi: 10.3760/cma.j.issn.1673-4114.2017.06.014

点击查看大图

计量

文章访问数: 2087
HTML全文浏览量: 487
PDF下载量: 5

PET-CT在胃肠道间质瘤中的应用

冼伟均
冯彦林^,

通讯作者: 冯彦林, jambool@126.com

佛山市第一人民医院核医学科, 佛山 528000

收稿日期: 2009-02-19

关键词:

摘要: 胃肠道间质瘤是一种主要生长在胃肠道的具有恶性潜能的间叶源性肿瘤,由于缺乏特异性的体征,影像学检查是诊断胃肠道间质瘤的重要辅助方法。PET-CT在胃肠道间质瘤的分期、疗效评价及随访方而与常规影像学检查相比,均表现出独特的优越性,该文综述了PET-CT及相关影像学技术在胃肠道间质瘤方面的应用价值。